









Markets
/
Stocks
/
nasdaq-rcus
/

Arcus Biosciences Inc

RCUS

21.030USD

+0.995+4.97%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

2.25BMarket Cap

LossP/E TTM



Arcus Biosciences Inc

21.030

+0.995+4.97%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Arcus Biosciences Inc

Currency: USD Updated: 2026-02-06

Key Insights

Arcus Biosciences Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 120 out of 392 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 33.00.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Arcus Biosciences Inc's Score

Industry at a Glance

Industry Ranking

120 / 392

Overall Ranking

256 / 4521

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Arcus Biosciences Inc Highlights

StrengthsRisks

Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company has a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 130.36% year-on-year.

Undervalued

The company’s latest PE is -6.16, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 74.62M shares, decreasing 7.42% quarter-over-quarter.

Held by PRFDX

Star Investor PRFDX holds 21.29K shares of this stock.

Analyst Rating

Based on 12 analysts

Buy

Current Rating

33.000

Target Price

+64.75%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Arcus Biosciences Inc is 6.00, ranking 301 out of 392 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 26.00M, representing a year-over-year decrease of 45.83%, while its net profit experienced a year-over-year decrease of 46.74%.

Score

Industry at a Glance

Previous score

6.00

Change



Financials

5.93

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.26

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

3.78

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

5.96

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.07

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Arcus Biosciences Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Arcus Biosciences Inc is 6.23, ranking 310 out of 392 in the Biotechnology & Medical Research industry. Its current P/E ratio is -6.16, which is -73.65% below the recent high of -1.62 and -24.11% above the recent low of -7.65.

Score

Industry at a Glance

Previous score

6.23

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 120/392

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Arcus Biosciences Inc is 8.17, ranking 158 out of 392 in the Biotechnology & Medical Research industry. The average price target is 32.00, with a high of 56.00 and a low of 16.00.

Score

Industry at a Glance

Previous score

8.17

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 12 analysts

Buy

Current Rating

33.000

Target Price

+64.75%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

542

Total

Median

Average

Company name

Ratings

Analysts

Arcus Biosciences Inc

RCUS

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

109

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Arcus Biosciences Inc is 6.66, ranking 199 out of 392 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 23.78 and the support level at 19.10, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.29

Change

0.37

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(2)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.334

Sell

RSI(14)

45.257

Neutral

STOCH(KDJ)(9,3,3)

22.112

Neutral

ATR(14)

1.143

Low Volatility

CCI(14)

-113.834

Sell

Williams %R

71.059

Sell

TRIX(12,20)

-0.260

Sell

StochRSI(14)

65.602

Buy

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

21.134

Sell

MA10

21.567

Sell

MA20

21.948

Sell

MA50

22.998

Sell

MA100

19.942

Buy

MA200

14.681

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Arcus Biosciences Inc is 5.00, ranking 139 out of 392 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 60.74%, representing a quarter-over-quarter increase of 16.22%. The largest institutional shareholder is The Vanguard, holding a total of 7.94M shares, representing 6.47% of shares outstanding, with 2.56% increase in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Gilead Sciences Inc

31.42M

BlackRock Institutional Trust Company, N.A.

10.06M

-0.31%

The Vanguard Group, Inc.

Star Investors

6.62M

+1.12%

Point72 Asset Management, L.P.

Star Investors

4.33M

-27.39%

Woodline Partners LP

3.77M

-5.76%

Suvretta Capital Management, LLC

3.69M

State Street Investment Management (US)

3.39M

-6.50%

Rosen Terry Jay

2.51M

-2.22%

Fidelity Management & Research Company LLC

1.99M

-12.23%

Invus Financial Advisors, LLC

1.61M

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Arcus Biosciences Inc is 4.64, ranking 74 out of 392 in the Biotechnology & Medical Research industry. The company's beta value is 0.85. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.